Freeline Therapeutics Holdings PLC ADR (FRLN): Price and Financial Metrics
GET POWR RATINGS... FREE!
FRLN Stock Price Chart Interactive Chart >
FRLN Price/Volume Stats
| Current price | $0.76 | 52-week high | $15.40 |
| Prev. close | $0.69 | 52-week low | $0.65 |
| Day low | $0.70 | Volume | 18,700 |
| Day high | $0.76 | Avg. volume | 686,128 |
| 50-day MA | $0.93 | Dividend yield | N/A |
| 200-day MA | $2.06 | Market Cap | 27.24M |
Freeline Therapeutics Holdings PLC ADR (FRLN) Company Bio
Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani on April 3, 2020 and is headquartered in Stevenage, the United Kingdom.
Latest FRLN News From Around the Web
Below are the latest news stories about Freeline Therapeutics Holdings plc that investors may wish to consider to help them evaluate FRLN as an investment opportunity.
2 Net Current Asset Value Stocks to ConsiderShort-term investors could be interested in these businesses |
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™FLT190 well-tolerated with promising early efficacy in Fabry disease including sustained α-Gal A expression up to two years GALILEO-1, a first-in-human, open-label, international, multicenter Phase 1/2 clinical trial evaluating FLT201 in Gaucher disease Type 1 initiated LONDON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people wi |
Freeline grants inducement options to three new employeesFreeline Therapeutics (NASDAQ:FRLN) granted three newly hired employees non-statutory options to purchase 66.4K of its shares. Each of the options has an exercise price of $1.18/share. The options have a maximum 10-year term and vest over a 4-year service period, with 25% of the award vesting on the first anniversary of... |
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that on January 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 66,400 of the Companys ordinary shares. |
Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and DiscoveryStennicke, an industry veteran, will join Freeline to lead the research and advancement of the Company’s innovative science and platform technologyLONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies for people with inherited systemic debilitating diseases, today announced the expansion of its |
FRLN Price Returns
| 1-mo | -15.56% |
| 3-mo | -28.30% |
| 6-mo | -67.24% |
| 1-year | -93.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -61.62% |
| 2021 | -89.16% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...